Benefits
Small rise in energy expenditure, and none measurable in leaner people
A meta-analysis of 9 human trials found capsaicin or its non-pungent relative capsiate raised energy expenditure by 58.6 kcal/day and lowered the respiratory quotient by 0.216. The effect was confined to trials whose participants averaged a BMI above 25; in trials of leaner participants there was no measurable change in energy expenditure or in respiratory quotient. Around 59 kcal is roughly half a banana, so this is not a meaningful weight-loss driver on its own. Mechanism: TRPV1-mediated sympathetic activation.
Shift toward fat oxidation (a laboratory marker, not a performance or fat-loss result)
Capsaicinoid intake lowers the respiratory quotient, a gas-exchange marker meaning a larger share of fuel came from fat. That is a laboratory measure, not a measured change in body fat or in what an athlete can do. A meta-analysis of 14 exercise studies (183 participants, usually 12 mg taken 45 minutes beforehand, pooling capsaicin with its non-pungent relative capsiate) found no improvement in aerobic endurance and only a small gain in muscular endurance, about 0.27 standard deviations on repetitions to failure. Perceived exertion was slightly lower after the muscular endurance tests but not after the aerobic ones.
Appetite and energy intake regulation
A meta-analysis pooling 8 trials in 191 people found capsaicinoids taken before a meal cut what people then ate by about 74 kcal at that meal, with at least 2 mg needed for any effect. Heterogeneity between trials was high (I2 = 75.7 percent), and what was measured was a single meal, not a day, a week or a kilogram of body weight.
Cholesterol, blood pressure and blood sugar: no reliable effect
A 2026 meta-analysis of 13 randomized trials in 821 adults found no effect of red pepper or capsaicin supplementation on triglycerides, LDL, HDL, systolic blood pressure, fasting glucose, insulin, HOMA-IR or HbA1c. Small reductions in total cholesterol and diastolic blood pressure vanished when a single study was removed, and the authors graded the certainty of the evidence as low to very low. Mechanism likely involves combined metabolic effects rather than direct lipid pathway modulation.
Topical capsaicin for pain (skin route, not what this oral capsule does)
Topical capsaicin creams are well-established for localized pain applications (osteoarthritis, neuropathic pain) — mechanism involves repeated TRPV1 activation leading to substance P depletion and reduced pain signaling. This is a topical cream/patch use and is distinct from anything an oral capsule can do — oral capsaicin supplements do not deliver this localized pain effect.
GI and circulatory traditional uses
Cayenne has extensive traditional use for digestion, circulation, and as a general stimulant. Human evidence for the digestive claim is thin: in one crossover study, 18 healthy volunteers who ate 20 g of chili before a 600 mg aspirin dose had less endoscopic stomach damage than when they took the aspirin alone. That was chili eaten as food in a single-dose experiment, not a capsule taken daily, and the usual effect of supplemental capsaicin on the stomach is burning.
Mechanism of action
TRPV1 receptor activation
Capsaicinoids activate the TRPV1 (transient receptor potential vanilloid 1) thermal-sensing ion channel — also activated by heat above ~43°C. TRPV1 is expressed on sensory neurons (creating the 'hot' sensation) and also on various peripheral tissues where activation triggers metabolic and circulatory effects.
Sympathetic nervous system activation
TRPV1 activation drives sympathetic responses including catecholamine release (norepinephrine, epinephrine) — the same neurotransmitters that drive the 'fight or flight' response. These catecholamines mobilize fatty acids from adipose tissue and increase basal metabolic rate.
Brown adipose tissue (BAT) thermogenesis
Capsaicinoid-triggered sympathetic activity stimulates brown adipose tissue — the metabolically active fat depot that produces heat by uncoupling mitochondrial respiration (via UCP1). Brown fat activation is one proposed mechanism for the small rise in energy expenditure seen after capsaicinoid intake; it has not been shown to be the reason for any change in body weight in people.
Fat oxidation pathway upregulation
TRPV1 activation upregulates fatty acid oxidation enzymes (CPT1, ACO) and downregulates lipogenesis. The net effect is increased fat utilization as fuel — observable as reduced respiratory quotient (more fat vs carbs oxidized) during exercise and rest.
TRPV1 desensitization (chronic use)
Chronic TRPV1 activation can produce receptor desensitization — explaining the tolerance development seen with regular capsaicin use (less burning sensation over time). The metabolic effects may also attenuate with chronic exposure, supporting cyclical use rather than continuous supplementation.
Clinical trials
Multiple acute crossover trials and pooled analyses evaluating capsaicinoid intake (from chili pepper extracts and isolated capsaicinoids) for effects on resting energy expenditure, thermogenesis, and respiratory quotient. Doses ranged from 2-10 mg total capsaicinoids per day. Indirect calorimetry and ventilated hood methodology across trials.
Adults across 9 pooled trials; acute single-dose and short-term protocols. The effect appeared only in trials whose participants averaged a BMI above 25, not in leaner participants.
Pooling 9 human trials, capsaicin or capsinoid intake raised energy expenditure by 58.6 kcal/day (p = 0.030) and lowered the respiratory quotient by 0.216 (p = 0.031), indicating a shift toward fat oxidation. In trials whose participants averaged a BMI below 25 there was no effect on either outcome. Dose-response relationship: 2-10 mg capsaicinoids/day is the effective range; higher doses limited by GI tolerability with unprotected capsaicin formulations.
Pooled analyses pooling 8-12+ week capsaicinoid supplementation trials for body weight, body fat, and waist circumference outcomes. Trials used a range of capsaicin/capsicum products at doses delivering 2-10 mg total capsaicinoids per day. Most trials conducted in overweight or obese adults alongside caloric-deficit interventions.
Overweight and obese adults across pooled trials. 8-12+ week supplementation periods.
Pooling 15 randomized trials in 762 adults, capsaicin supplementation reduced body weight by 0.51 kg, BMI by 0.25 kg/m2 and waist circumference by 1.12 cm versus control. Those differences are statistically significant and clinically small: about half a kilogram over the length of a trial. Effects most pronounced when combined with diet and exercise interventions; capsaicinoids should be viewed as one component of a comprehensive weight management approach, not a standalone fat-loss intervention. No serious safety signals at the 2-10 mg/day range.
Capsaicin in topical cream (0.025-0.075%) and high-dose patch (8%) formulations is FDA-approved and extensively studied for localized pain applications including osteoarthritis, post-herpetic neuralgia, and diabetic neuropathy. Mechanism distinct from oral metabolic applications: repeated topical TRPV1 activation depletes substance P from sensory neurons, reducing pain signaling over time.
Adults with localized chronic pain conditions. Multi-week to ongoing topical application protocols.
Topical capsaicin produces clinically meaningful pain reduction in osteoarthritis, neuropathic pain (post-herpetic and diabetic), and musculoskeletal pain across multiple controlled trials. Initial burning sensation typical with application; effect emerges over 1-2 weeks of consistent use as substance P depletion accumulates. Well-tolerated and non-systemic — distinct safety profile from oral capsaicin.